

Atty's Docket: 101195-63

IN THE CLAIMS

Amend the claims in accordance with the following:

1. (Previously presented) An immunoadsorber for blood treatment use in sepsis therapy, the immunoadsorber comprising a carrier of organic or synthetic polymers to which are immobilized antibodies that bind C3a and/or C5a and to lipopolysaccharides (LPS) and wherein,
 - a) the antibodies to C3a are specific for at least one peptide selected from the group consisting of SEQ ID NO: 1, 2, and 3; and
 - b) the antibodies to C5a are specific for at least one peptide selected from the group consisting of SEQ ID NO: 4, and 5.
2. (Previously presented) The immunoadsorber according to Claim 1, wherein the antibodies are polyclonal antibodies.
3. (Previously presented) The immunoadsorber according to Claim 2, wherein the antibodies are avian antibodies of type IgY.
4. (Currently amended) The immunoadsorber of Claim 1, wherein the specific immobilized antibodies comprising the immunoadsorber specific for sepsis mediators are varied as a function of the actual content of sepsis mediators in the blood.
5. (Currently amended) The immunoadsorber according to Claim 1, wherein further comprising the at least one antibody antibodies are specific for directed against at least one sepsis mediator selected from the group consisting of TNF, 1L1, 1L6, IL8 and/or IL10.
6. (Canceled).
7. (Currently amended) The immunoadsorber according to Claim 5, wherein the bound immobilized antibodies are specific for at least one of the following peptide sequences of the interleukins 1 α and 1 β

Atty's Docket: 101195-63

IL1 α : NH2-NCYSENEEDSSSID-COOH SEQ ID NO. 6

NH2-GAYKSSKDDAKIT-COOH SEQ ID NO. 7

NH2-WETHGKKNYFTS-COOH SEQ ID NO. 8

IL β : NH2-RISDHYSKGFRQA-COOH SEQ ID NO. 9

NH2-VQGEESNDKIPVA-COOH SEQ ID NO. 10

NH2-ESVDPKNYPKKMEKRF-COOH SEQ ID NO. 11

8. (Currently amended) The immunoadsorber according to Claim 5, wherein the bound immobilized antibodies are specific for at least one of the following peptide sequences of interleukin 6:

IL6: NH2-APHRQPLTSSSERIDKQI-COOH SEQ ID NO. 12

NH2-QNRFESSEEQARA-COOH SEQ ID NO. 13

NH2-AITTPDPTTNAS-COOH SEQ ID NO. 14.

9. (Currently amended) The immunoadsorber according to Claim 5, wherein the bound immobilized antibodies are specific for at least one of the following peptide sequences of interleukin 10

IL10: NH2-SPGQGTQSENSCT-COOH SEQ ID NO. 15

NH2-QMKDQLDNLLLKES-CCOH SEQ ID NO. 16

NH2-MPQAENQDPDIKA-COOH SEQ ID NO. 17

NH2-LPCENKS KAVEQ-COOH SEQ ID NO. 18.

10. (Currently amended) The immunoadsorber according to Claim 5, wherein the bound immobilized antibodies are specific for at least one of the following peptide sequences of TNF α

TNF α : NH2-VRSSSRTPSDKPVA-COOH SEQ ID NO. 19

NH2-KSPCQRETPEGAEAKPW-COOH SEQ ID NO. 20.

Atty's Docket: 101195-63

11. (Currently amended) The immunoadsorber according to Claim 1, wherein the organic or synthetic carrier material polymers further comprise comprises membranes or particles of one or more of the group consisting of polystyrenes, carbohydrates including cellulose or agarose derivatives, or and acrylates.

12. (Currently amended) The immunoadsorber according to Claim 1, wherein the immobilized specific antibodies are covalently bound to the carrier.

13. (Currently amended) The immunoadsorber according to Claim 1, wherein the immobilized antibodies are fixed-attached to the carrier materials via spacers or linkers.

14. (Currently amended) A method for the production of immunoadsorber according to Claim 1, wherein antibodies aimed-specific for against C3a and/or C5a and LPS and, optionally, against further sepsis mediators are covalently or adsorptively coupled to the carrier materials of organic or synthetic polymers.

15. (Currently amended) A method according to Claim 14, wherein the antibodies are produced by immunisation of small-mammals, including mice, rats or rabbits, or of birds, including chickens, with the corresponding antigens.

16. – 17. (Canceled).

18. (Currently amended) A method of performing sepsis therapy of blood with treating blood plasma or serum using the immunoadsorber of claim 1, the method comprising the steps of,

providing an amount of blood plasma or serum in need of sepsis therapy; and contacting the blood with the immunoadsorber of claim 1;

wherein the blood in contact with the immunoadsorber is either whole blood, or whole blood that had first been subjected to hemofiltration and/or concentration and/or dilution, prior to contacting the immunoadsorber and recovering the treated blood plasma or serum from the immunoadsorber.

Atty's Docket: 101195-63

19. (Currently amended) The method of claim 18, wherein the blood plasma or serum has not been subjected to hemofiltration prior to contacting the immunoadsorber.

20. to 21. (Canceled).

22. (Previously presented) An immunoadsorber for use in sepsis therapy, the immunoadsorber comprising a carrier of organic or synthetic polymers to which are immobilized avian antibodies specific for C3a and/or C5a.

23. (Previously presented) The immunoadsorber of claim 22, wherein the avian antibody is a chicken antibody.

24. (Previously presented) The immunoadsorber of claim 22, wherein the avian antibody is specific for a peptide selected from the group consisting of SEQ ID NO: 1 to 5.

25. (Previously presented) The immunoadsorber of claim 22, wherein the avian antibody does not activate the complement system.

26. (Previously presented) The immunoadsorber of claim 23, wherein the chicken antibody does not activate the complement system.

27. (Previously presented) The immunoadsorber of claim 23, wherein the chicken antibody is specific for a peptide selected from the group consisting of SEQ ID NO: 1 to 5.

28. (New) The method of claim 15 wherein the antibodies are raised by immunizing one or more animals selected from the group consisting of mice, rats, rabbits or chickens.